The FDA’s fast track designation of LYT-200 in this population is supported by an ongoing phase 1/2 clinical trial.
LYT-200, an antibody directed against galectin-9, has been granted a fast track designation by the FDA for the treatment of patients with recurrent or metastatic HNSCC, according to PureTech Health.1
The fast track designation was created to streamline the development and assessment of drugs that fill serious unmet needs.
“In the US, there are approximately 66,000 people diagnosed with head and neck cancers each year, and the prognosis for metastatic disease is unfavorable, with a median survival rate of about 10 months,” said Eric Sherman, MD, Memorial Sloan Kettering Cancer Center and an investigator in PureTech’s phase 1/2 clinical trial, in a press release. “There is an important need to explore promising new mechanisms and targets such as galectin-9 to bring therapeutic innovation to this patient population.”
LYT-200 is the subject of 2 ongoing clinical trials. A phase 1/2 trial (NCT04666688) is evaluating the agent alone and in combination with chemotherapy or tislelizumab (Tevimbra) in patients with locally advanced or metastatic solid tumors, including HNSCC.2 The study’s primary end points are safety, tolerability, and preliminary efficacy. Secondary end points include pharmacokinetics and pharmacodynamics.
Part 1 of the study is a dose escalation of single-agent LYT-200, followed by dose expansion of LYT-200 plus gemcitabine/nab-paclitaxel or tislelizumab. Part 2 of the study is a combination dose expansion based on outcomes from part 1.
Patients with HNSCC or urothelial carcinoma are eligible for enrollment in the study, which is recruiting across sites in California, Colorado, Florida, Massachusetts, Michigan, New York, Tennessee, and Texas.
“By granting fast track designation to LYT-200 for head and neck cancers, the FDA continues to highlight areas of critical need within oncology as well as the potential for LYT-200,” said Aleksandra Filipovic, MD, PhD, head of oncology at PureTech, in a press release.1 “As galectin-9’s role in suppressing immune-mediated activity has been well-validated, it represents an important area of clinical research, especially in aggressive cancers with increased mortality.”
The FDA granted an orphan drug designation to LYT-200 in AML in March 2024.1 A phase 1 study (NCT05829226) is investigating the agent in patients with relapsed/refractory AML or myelodysplastic syndrome.3
FDA Accepts sBLA of Dostarlimab/Chemo to Include All Advanced Endometrial Cancer
April 24th 2024The FDA accepted the supplemental biologics license for dostarlimab plus standard-of-care chemotherapy for all patients with primary advanced or recurrent endometrial cancer and set a Prescription Drug User Fee Act action date of August 23, 2024.
Read More
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More